Center for Digestive and Liver Diseases, Inc.  © 2013  |  Privacy policy

like us

Protocol GA28950

 

A Phase III, Double Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Etrolizumab During Induction and Maintenance in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Refractory to or Intolerant of TNF Inhibitors

 

 

 

I am interested in more information about this study.

 
SEND CLEAR